The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

The Effects of Qingfei Paidu Decoction on Coronavirus Disease-19: A Narrative Review

COVID-19에 대한 청폐배독탕의 연구 동향 분석

  • Kang, Bo-hyung (Dept. of Korean Internal Medicine, College of Korean Medicine, Gachon University) ;
  • Choi, You-kyoung (Dept. of Korean Internal Medicine, College of Korean Medicine, Gachon University) ;
  • Jeon, Chan-yong (Dept. of Korean Internal Medicine, College of Korean Medicine, Gachon University) ;
  • Yang, Seung-Bo (Dept. of Korean Internal Medicine, College of Korean Medicine, Gachon University)
  • 강보형 (가천대학교 한의과대학 한방내과교실) ;
  • 최유경 (가천대학교 한의과대학 한방내과교실) ;
  • 전찬용 (가천대학교 한의과대학 한방내과교실) ;
  • 양승보 (가천대학교 한의과대학 한방내과교실)
  • Received : 2020.05.29
  • Accepted : 2020.07.03
  • Published : 2020.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Qingfei Paidu decoction is recommended for treatment and prevention of COVID-19. It is a prescription that combines Mahaenggamseok-tang, Oryeong-san, Soshiho-tang, Saganmahwang-tang, and Kwakhyangjeonggi-san. According to several clinical reviews, symptoms of COVID-19 were improved, laboratory test indicators were improved, and the cure rate was increased. Pharmacologically, the Qingfei Paidu decoction and its composition have been reported to inhibit viral replication, alleviate immune responses, and have anti-inflammatory and antiviral effects. Severe side effects were not revealed, and this treatment is considered relatively safe. However, to validate and better understand these findings, well-designed clinical studies are needed.

Keywords

References

  1. 장인수, 양승보, 백유상, 정창현, 장우창, 권승원, 등. 코로나바이러스감염증-19 한의진료 권고안. 2nd edition. 서울: 사단법인대한한의사협회; 2020, p. 1-52.
  2. Lau JT, Leung P, Wong E, Fong C, Cheng K, Zhang S, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. Journal of Alternative & Complementary Medicine 2005;11(1):49-55. https://doi.org/10.1089/acm.2005.11.49
  3. Yang ZF, Leung ELH, Liu L, Jiang ZH, Zhong N. Developing influenza treatments using traditional Chinese medicine. Science 2015;347(6219):S35-S7.
  4. Jiang L, Deng L, Wu T. Chinese medicinal herbs for influenza. Cochrane Database of Systematic Reviews 2013;(3):CD004559.
  5. Jiang YJ, Lian YJ, Li J, Liu HX. Study on Pneumonia Prescription of Traditional Chinese Medicine to Prevent Novel Coronavirus Infection in Different Regions Based on Data Mining. World Chinese Medicine 2020;15(3):325-31.
  6. Wang X, Liu Z. Prevention and treatment of viral respiratory infections by traditional Chinese herbs. Chinese medical journal 2014;127(7):1344-50. https://doi.org/10.3760/cma.j.issn.0366-6999.20132029
  7. Shen AM, Zhang W, Wu Z, Wang WL, Hua JJ. TCM Theory analysis of Qing-Fei-Pai-Du-Tang in treating COVID-19. Liaoning Journal of Traditional Chinese Medicine 2020;(3):106-8.
  8. 恵子 小. COVID-19 感染症に対する漢方治療の考え方. 日本の感染学会 2020;3:1-5.
  9. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. International journal of biological sciences 2020;16(10):1708-17. https://doi.org/10.7150/ijbs.45538
  10. 이범준, 정희재, 최준용, 김관일. 코로나바이러스감염증-19 한의지료 지침. 2.1 edition. 서울: 전국한의과대학폐계내과협의회; 2020, p. 1-13.
  11. 고흥, 손성세, 송미덕, 윤성중, 윤종현, 이범준, 등. 코로나바이러스감염증-19 한의전화진료 가이드. 1st edition. 서울: 사단법인대한한의사협회; 2020, p. 1-45.
  12. 薛伯寿, 姚魁武, 薛燕星. "清肺排毒汤" 快速有效治疗新型冠状病毒肺炎的中医理论分析. 中医杂志 2020;61(6):461-2.
  13. Wang RQ, Yang SJ, Xie CG, Shen QL, Li MQ, Lei X, et al. Clinical Observation of Qingfeipaidu Decoction in the Treatment of COVID-19. Pharmacology and Clinics of Chinese Materia Medica 2020;36(1):13-8.
  14. 路志正 路. "清肺排毒汤" 彰显中医药抗疫疗效与自信. 中医杂志 2020;10:833-4.
  15. Wu H, Wang JQ, Yang YW, Li TY, Cao YJ, Qu YX, et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology. Acta Pharmaceutica Sinica 2020;55(3):374-83.
  16. Zhao J, Tian SS, Yang J, Liu JF, Zhang WD. Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology. Chin Trad Herbal Drugs 2020;51(4):829-35.
  17. 진조조. 중의치법과 방제. 서울: 정담; 2009, p. 306, 527, 300, 1170.
  18. Zhang HL, Huang ZG, Jiang X, Qiu Y, Huang TM, Lin ZQ, et al. Study on the Mechanism of Maxing Shigan Decoction in the Treatment of the Severe Novel Coronavirus Pneumonia Based on Network Pharmacology. Journal of Chinese Medicinal Materials 2000;(03):1-8.
  19. Hsieh CF, Lo CW, Liu CH, Lin S, Yen HR, Lin TY, et al. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. Journal of ethnopharmacology 2012;143(1):57-67. https://doi.org/10.1016/j.jep.2012.05.061
  20. Zhong Y, Zhou J, Liang N, Liu B, Lu R, He Y, et al. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. Intervirology 2016;59(5-6):267-74. https://doi.org/10.1159/000458726
  21. Kao ST, Yeh TJ, Hsieh CC, Shiau HB, Yeh FT, Lin JG. The effects of Ma-Xing-Gan-Shi-Tang on respiratory resistance and airway leukocyte infiltration in asthmatic guinea pigs. Immunopharmacology and immunotoxicology 2001;23(3):445-58. https://doi.org/10.1081/IPH-100107343
  22. 吉益東洞. 약징. 서울: 청홍; 2010, p. 95-100, 61-4.
  23. 한방약리학교재편찬위원회. 한방약리학. 서울: 신일북스; 2015, p. 119-30, 321-8.
  24. 한의과대학방제학교실. 방제학. 서울: 영림사; 2009, p. 504-5.
  25. Matsukawa T, Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2011;300(3):R624-R9. https://doi.org/10.1152/ajpregu.00324.2010
  26. Boldt J, Suttner S. Physiology and pathophysiology of the natriuretic peptide system. Yearbook of Intensive Care and Emergency Medicine. Berlin, Heidelberg: Springer; 2006, p. 101-9.
  27. Task Force for Clinical Practice Guidelines (CPG-TF) Committee for EBM. Clinical Practice Guidelines Containing kampo Products in Japan(KCPG) Appendix 2018. The Japan Society for Oriental Medicine (JSOM). 2019, p. 1-8.
  28. 中国中西医结合杂志. 新型冠状病毒肺炎诊疗方案(试行第五版 修正版). 中国中西医结合杂志 2020;40(2):136-8.
  29. Furukawa M, Sakashita H, Kamide M, Umeda R. Inhibitory effects of kampo medicine on Epstein-Barr virus antigen induction by tumor promoter. Auris Nasus Larynx 1990;17(1):49-54. https://doi.org/10.1016/S0385-8146(12)80021-6
  30. Yamashiki M, Nishimura A, Huang XX, Nobori T, Sakaguchi S, Suzuki H. Effects of the Japanese herbal medicine "Sho-saiko-to"(TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis. Clinical and Developmental Immunology 1999;7(1):17-22. https://doi.org/10.1155/1999/62564
  31. Yamashiki M, Nishimura A, Suzuki H, Sakaguchi S, Kosaka Y. Effects of the Japanese herbal medicine "Sho-Saiko-To"(TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 1997;25(6):1390-7. https://doi.org/10.1002/hep.510250615
  32. Yamashiki M, Nishimura A, Nobori T, Nakabayashi S, Takagi T, Inoue K, et al. In vitro effects of Sho-saiko-to on production of granulocyte colony-stimulating factor by mononuclear cells from patients with chronic hepatitis C. International journal of immunopharmacology 1997;19(7):381-5. https://doi.org/10.1016/S0192-0561(97)00064-7
  33. Kubo T, Nishimura H. Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. Phytomedicine 2007;14(2-3):96-101. https://doi.org/10.1016/j.phymed.2006.09.015
  34. 川村研一. インフルエンザ患者に対する麻黄湯の有効性の検討. 日本臨床内科医会会誌 2007;22(4):435-8.
  35. 芦原貴司. ザナミビルに麻黄湯を併用し緩徐な解熱が得られた小児インフルエンザの 1 症例. 漢方医学 2010;34(2):201-3.
  36. 陈豪, 陈军红, 沈旭波, 吕可君. 射干麻黄汤对哮喘性肺炎大鼠肺部炎症反应及免疫反应的影响. 广州中医药大学学报 2020;37(2):317-23.
  37. Shijie Z, Moriya J, Yamakawa Ji, Chen R, Takahashi T, Sumino H, et al. Mao-to prolongs the survival of and reduces $TNF-{\alpha}$ expression in mice with viral myocarditis. Evidence-Based Complementary and Alternative Medicine 2010;7(3):341-9. https://doi.org/10.1093/ecam/nen010
  38. Orihara Y, Hamamoto H, Kasuga H, Shimada T, Kawaguchi Y, Sekimizu K. A silkworm-baculovirus model for assessing the therapeutic effects of antiviral compounds: characterization and application to the isolation of antivirals from traditional medicines. Journal of general virology 2008;89(1):188-94. https://doi.org/10.1099/vir.0.83208-0
  39. Murakami T, Harada H, Suico MA, Shuto T, Suzu S, Kai H, et al. Ephedrae herba, a component of Japanese herbal medicine Mao-to, efficiently activates the replication of latent human immunodeficiency virus type 1 (HIV-1) in a monocytic cell line. Biological and Pharmaceutical Bulletin 2008;31(12):2334-7. https://doi.org/10.1248/bpb.31.2334
  40. Park JS, Woo MS, Kim DH, Hyun JW, Kim WK, Lee JC, et al. Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells. Journal of Pharmacology and Experimental Therapeutics 2007;320(3):1237-45. https://doi.org/10.1124/jpet.106.114322
  41. Kang KA, Zhang R, Piao MJ, Ko DO, Wang ZH, Kim BJ, et al. Protective effect of irisolidone, a metabolite of kakkalide, against hydrogen peroxide induced cell damage via antioxidant effect. Bioorganic & medicinal chemistry 2008;16(3):1133-41. https://doi.org/10.1016/j.bmc.2007.10.085
  42. Zhao M, Chen Y, Wang C, Xiao W, Chen S, Zhang S, et al. Systems pharmacology dissection of multi-scale mechanisms of action of Huo-Xiang-Zheng-Qi formula for the treatment of gastrointestinal diseases. Frontiers in Pharmacology 2019;9:1448. https://doi.org/10.3389/fphar.2018.01448
  43. Li X, Xie P, Hou Y, Chen S, He P, Xiao Z, et al. Tangeretin inhibits oxidative stress and inflammation via upregulating Nrf-2 signaling pathway in collagen-induced arthritic rats. Pharmacology 2019;104(3-4):187-95. https://doi.org/10.1159/000501163
  44. Zhao S, Liu Z, Wang M, He D, Liu L, Shu Y, et al. Anti-inflammatory effects of Zhishi and Zhiqiao revealed by network pharmacology integrated with molecular mechanism and metabolomics studies. Phytomedicine 2018;50:61-72. https://doi.org/10.1016/j.phymed.2018.09.184
  45. Kim SJ, Park SK. Antioxidative and Anti-inflammatory Effects of Aurantii Fructus Immaturus Pharmacopuncture. Korean Journal of Acupuncture 2010;27(2):13-24.
  46. Choi GY, Kim BW. Experimental Study on the Antioxidant and Antimicrobial Properties of Dioscoreae Rhizoma. The Journal of Korean Oriental Internal Medicine 2010;31(2):290-7.
  47. Kim MJ, Kim HN, Kang KS, Baek NI, Kim DK, Kim YS, et al. Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis. International immunopharmacology 2004;4(12):1489-97. https://doi.org/10.1016/j.intimp.2004.07.001
  48. Yang JM, Lee JH, Sung JS, Kim DI. Proteomic Approach to Study the Antioxidant Activities of Dioscoreae Rhizoma on HeLa Cells. The Journal of Oriental Gynecology 2008;21(2):108-24.
  49. Jun YJ, Son MY, Khil MJ, Sung JS, Jeong JC, Kim DI. Cell differentiation and Anti-oxydative effect of Dioscoreae Rhizoma on HeLa Cell. The Journal Of Oriental Gynecology 2007;20(2):139-54.
  50. Shin SW, Lee YS, Park JH, Kwon TK, Suh SI, Kwon YK. Comparison of Immunomodualtory Effects of Water-extracted Ginseng Radix, Pilose Asia-bell, Astragali Radix, Astractylodes Rhizoma alba and Dioscoreae Rhizoma. Korean Journal of Oriental Physiology & Pathology 2004;18(4):1140-6.
  51. Ryu HC, Shin JG. A study on proper dosage of Ma-huang(麻黃). The Journal of Korean Medical Association of Clinical Sanghan-Geumgwe 2013;5(1):101-11.
  52. Kim HS, Lee SI. A Study for Safe Dose and Clinical Use of Glycyrrhizae Radix in Shanghanlun. The Journal of Korean Medical Association of Clinical Sanghan-Geumgwe 2016;8(1):1-23.
  53. Lee I, Park SM, Park SC, Kim DH, Cho MK, Han CW, et al. Overview of the Interaction between Warfarin and Korean Herbal Medicine. The Journal of Korean Oriental Internal Medicine 2012;33(2):160-71.
  54. Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. European Respiratory Journal 1996;9(12):2691-96. https://doi.org/10.1183/09031936.96.09122691